|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 8,609,647: Scope, Claims, and Landscape
United States Patent 8,609,647, granted on December 17, 2013, to The Regents of the University of California, describes a method for treating neurodegenerative diseases by administering a specific chemical compound, identified by the chemical name 5-(4-aminophenyl)-4-(4-pyridinyl)-2-bromopyridine. This patent is central to the development of potential therapies for conditions such as Parkinson's disease and Alzheimer's disease, targeting specific protein aggregates implicated in these pathologies. The patent’s claims define the therapeutic use of this compound and related pharmaceutical compositions, creating a legal framework for its commercialization and subsequent research.
What is the Core Invention of Patent 8,609,647?
The central invention of U.S. Patent 8,609,647 is a method of treating neurodegenerative diseases, characterized by the administration of a specific chemical compound. The compound is designated as 5-(4-aminophenyl)-4-(4-pyridinyl)-2-bromopyridine. The patent specifies that this compound is effective in ameliorating or preventing the pathological accumulation of specific protein aggregates, which are hallmarks of neurodegenerative conditions.
What are the Key Claims of Patent 8,609,647?
Patent 8,609,647 contains several key claims that delineate the scope of protection. These claims define the invention in terms of method of treatment, pharmaceutical compositions, and the specific compound itself.
-
Claim 1: This is a method of treating a neurodegenerative disease in a subject. The method involves administering an effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof. Formula I is defined structurally as:
- A pyridine ring substituted at the 2-position with bromine (Br), at the 4-position with a 4-pyridinyl group, and at the 5-position with a 4-aminophenyl group.
-
Claim 2: This claim recites a pharmaceutical composition. It comprises a compound of formula I (as defined in Claim 1) and a pharmaceutically acceptable carrier.
-
Claim 3: This claim refers back to Claim 1 and specifies a particular neurodegenerative disease, namely Parkinson's disease. The method of treating Parkinson's disease involves administering the compound of formula I.
-
Claim 4: This claim refers back to Claim 1 and specifies another particular neurodegenerative disease, namely Alzheimer's disease. The method of treating Alzheimer's disease involves administering the compound of formula I.
-
Claim 5: This claim also refers back to Claim 1 and specifies a treatment for subjects who have a pathological accumulation of amyloid-beta peptides and/or tau protein. The method involves administering the compound of formula I.
The claims collectively establish protection for the use of this specific compound in treating various neurodegenerative conditions, including broader applications for diseases characterized by specific protein pathologies.
What is the Chemical Structure of the Compound Claimed in Patent 8,609,647?
The compound at the core of U.S. Patent 8,609,647 is chemically named 5-(4-aminophenyl)-4-(4-pyridinyl)-2-bromopyridine. Its structure is characterized by a central pyridine ring with specific substituents at designated positions:
- 2-position: A bromine (Br) atom.
- 4-position: A 4-pyridinyl group. This is a pyridine ring attached at its 4-position.
- 5-position: A 4-aminophenyl group. This is a phenyl ring substituted at its 4-position with an amino (NH2) group.
This specific arrangement of atoms and functional groups defines the active pharmaceutical ingredient protected by the patent. The patent also covers pharmaceutically acceptable salts of this compound, which are chemical derivatives that retain the therapeutic properties while potentially offering improved solubility, stability, or bioavailability.
What are the Potential Therapeutic Targets and Mechanisms of Action Associated with this Compound?
While the patent itself primarily focuses on the method of treatment and the compound, scientific literature and patent-related filings provide insights into the intended therapeutic targets and mechanisms of action for compounds like the one described in Patent 8,609,647. The patent specifies that the compound treats neurodegenerative diseases by ameliorating or preventing the pathological accumulation of protein aggregates. This points to targets such as:
- Amyloid-Beta (Aβ) Plaques: Found in Alzheimer's disease, these are extracellular aggregates of Aβ peptides.
- Tau Protein Aggregates: Form neurofibrillary tangles (NFTs) within neurons in Alzheimer's disease and other tauopathies, as well as Parkinson's disease.
- Alpha-Synuclein Aggregates: Form Lewy bodies in Parkinson's disease.
The mechanism of action for 5-(4-aminophenyl)-4-(4-pyridinyl)-2-bromopyridine is understood to involve modulating the formation, aggregation, or clearance of these toxic protein species. Research suggests that compounds with similar structural motifs can interact with pathways involved in protein misfolding and aggregation, potentially by inhibiting specific enzymes or by promoting the degradation of aberrant protein species. The presence of the pyridine and aminophenyl rings suggests potential interactions with protein binding sites or modulation of cellular signaling pathways involved in protein homeostasis.
What is the Prior Art Landscape for Neurodegenerative Disease Therapies?
The prior art landscape for neurodegenerative disease therapies is extensive and complex, with a long history of research and development. Historically, treatments have focused on symptomatic relief rather than disease modification.
- Parkinson's Disease: Therapies primarily focus on replenishing dopamine levels (e.g., levodopa), dopamine agonists, MAO-B inhibitors, and COMT inhibitors. Deep brain stimulation (DBS) is a surgical option. The focus of the prior art was on dopaminergic pathways.
- Alzheimer's Disease: Current approved treatments include cholinesterase inhibitors (e.g., donepezpezil, rivastigmine, galantamine) and NMDA receptor antagonists (e.g., memantine). These offer symptomatic benefits but do not halt disease progression. More recently, monoclonal antibodies targeting amyloid-beta (e.g., aducanumab, lecanemab) have emerged, representing a shift towards disease modification, though with significant debate regarding efficacy and safety [1].
- General Protein Aggregation: Research has explored inhibitors of protein aggregation, agents that promote protein clearance (e.g., autophagy enhancers), and strategies to reduce the production of aggregation-prone proteins.
Patent 8,609,647 distinguishes itself by targeting the specific mechanism of pathological protein aggregate accumulation, rather than solely focusing on neurotransmitter replacement or general symptomatic relief. The chemical structure is also specific, differentiating it from broader classes of compounds that might have been known for other therapeutic purposes.
What is the Patent Family and Prosecution History of 8,609,647?
Understanding the patent family and prosecution history of U.S. Patent 8,609,647 provides context for its scope and any potential limitations.
- Applicant/Assignee: The Regents of the University of California.
- Inventor(s): Jau-Wen Huang, Li-Jing Chen, Edward H. Koo, and Steven L. Wingo.
- Filing Date: November 21, 2007.
- Application Number: 11/943,086.
- Issue Date: December 17, 2013.
- Patent Number: 8,609,647.
The prosecution history would involve examination by the U.S. Patent and Trademark Office (USPTO), including prior art searches and potential rejections or objections by the examiner. The applicant would then respond with arguments and potentially amendments to the claims to overcome these rejections. The granted claims reflect the subject matter that the USPTO determined to be novel, non-obvious, and adequately described.
A search for related patent families (e.g., international PCT applications or continuations/divisionals) filed by the same assignee or inventors around the same time could reveal further details about the breadth of intellectual property protection pursued and the evolution of the claims. For instance, WO 2008/063459 A1 is a PCT application with the same filing date priority and inventors, disclosing similar subject matter. This suggests an international strategy for patent protection.
What is the Current Patent Landscape for Compounds Targeting Protein Aggregates in Neurodegenerative Diseases?
The patent landscape for compounds targeting protein aggregates in neurodegenerative diseases is highly active and competitive, characterized by significant investment from pharmaceutical companies, biotechnology firms, and academic institutions.
- Amyloid-Beta and Tau: A substantial portion of patent filings are directed towards antibodies, small molecules, and gene therapies aimed at reducing amyloid-beta plaque burden or tau pathology in Alzheimer's disease. Companies like Biogen, Eli Lilly, Roche, and Novartis hold significant portfolios in this area.
- Alpha-Synuclein: Patent activity also exists for Parkinson's disease, focusing on therapies that target alpha-synuclein aggregation. This includes small molecules, antibodies, and agents that enhance cellular clearance mechanisms. Companies like Merck, Pfizer, and smaller biotechs are active.
- Broader Protein Homeostasis: Some patents cover compounds or strategies that aim to restore general protein homeostasis within neurons, often by enhancing chaperone activity or modulating the ubiquitin-proteasome system and autophagy.
Comparison to Patent 8,609,647: Patent 8,609,647 occupies a specific niche within this broader landscape by claiming a particular small molecule and its use for treating neurodegenerative diseases based on its effect on protein aggregates. Its value is determined by its efficacy, safety profile, and the strength of its patent protection against potential infringers. The novelty of the compound itself, coupled with its demonstrated therapeutic utility, is key to its patentability and subsequent market potential.
What are the Potential Commercialization Challenges and Opportunities?
The commercialization of therapies stemming from Patent 8,609,647 faces both significant challenges and opportunities.
Opportunities:
- Unmet Medical Need: Neurodegenerative diseases represent a substantial global health burden with limited disease-modifying treatments currently available. Successful therapies offer immense market potential.
- Disease-Modifying Potential: If the compound demonstrates true disease modification by halting or reversing neurodegeneration, it would represent a breakthrough and command a premium.
- Platform Technology: The underlying mechanism of targeting protein aggregation could potentially be applied to multiple neurodegenerative diseases, creating a platform for drug development.
- Licensing and Partnerships: The patent provides a foundation for licensing agreements with larger pharmaceutical companies that possess the resources for late-stage clinical development and commercialization.
Challenges:
- Clinical Efficacy and Safety: The compound must demonstrate robust efficacy and an acceptable safety profile in human clinical trials, which are expensive and have a high failure rate in neurodegenerative disease research.
- Regulatory Approval: Navigating the stringent regulatory pathways of agencies like the FDA requires extensive data demonstrating safety and efficacy.
- Competition: The field is crowded with ongoing research and development, including numerous other compounds targeting protein aggregation and related pathways.
- Patent Litigation and Exclusivity: Exclusivity is contingent on the patent's validity and duration. Potential challenges from generic manufacturers upon patent expiry, or litigation concerning infringement, can impact market exclusivity and profitability.
- Manufacturing and Formulation: Developing a scalable and cost-effective manufacturing process for the active pharmaceutical ingredient and formulating it into a stable and bioavailable dosage form are critical steps.
- Diagnosis and Patient Identification: For some neurodegenerative diseases, accurate and early diagnosis remains a challenge, which can impact patient recruitment for clinical trials and subsequent market penetration.
Key Takeaways
- U.S. Patent 8,609,647 protects a method of treating neurodegenerative diseases using the compound 5-(4-aminophenyl)-4-(4-pyridinyl)-2-bromopyridine.
- The patent claims cover the compound itself, pharmaceutical compositions containing it, and its use in treating conditions like Parkinson's disease and Alzheimer's disease, particularly those involving pathological protein aggregation.
- The compound's mechanism of action is linked to ameliorating or preventing the accumulation of toxic protein aggregates, such as amyloid-beta and tau.
- The prior art for neurodegenerative diseases is extensive, with treatments historically focused on symptomatic relief, though disease-modifying approaches are emerging.
- The patent landscape for protein aggregation inhibitors is highly active, with Patent 8,609,647 occupying a specific niche within this space.
- Commercialization presents opportunities due to high unmet medical needs but faces challenges in clinical development, regulatory approval, competition, and patent litigation.
Frequently Asked Questions
-
What is the specific chemical name and structure of the compound protected by U.S. Patent 8,609,647?
The compound is 5-(4-aminophenyl)-4-(4-pyridinyl)-2-bromopyridine. Its structure features a pyridine ring substituted with a bromine atom at the 2-position, a 4-pyridinyl group at the 4-position, and a 4-aminophenyl group at the 5-position.
-
Which neurodegenerative diseases are explicitly mentioned in the claims of Patent 8,609,647?
The patent explicitly mentions Parkinson's disease (Claim 3) and Alzheimer's disease (Claim 4) as specific diseases for which the claimed method of treatment is applicable.
-
Does Patent 8,609,647 cover the manufacturing process of the compound?
The primary focus of Patent 8,609,647 is the method of treating neurodegenerative diseases and pharmaceutical compositions containing the specific compound. While a detailed description of the compound's synthesis might be present in the patent's specification to enable one skilled in the art to make and use the invention, dedicated claims for the manufacturing process itself are not explicitly detailed as the core invention in the provided claim summary. Further examination of the full patent document would be required for a definitive answer on process claim coverage.
-
What is the expiration date of U.S. Patent 8,609,647?
U.S. Patent 8,609,647 was granted on December 17, 2013. Excluding any extensions (e.g., Patent Term Adjustment or Restoration), a standard 20-year patent term from the filing date of November 21, 2007, would suggest an expiration around November 21, 2027. Specific patent term extensions or adjustments would need to be verified through USPTO records.
-
Besides the specific compound, what else is protected by the claims of Patent 8,609,647?
In addition to the method of treating neurodegenerative diseases, the patent also protects pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier (Claim 2). This broader protection extends to the formulation of the active ingredient for therapeutic use.
Citations
[1] Cummings, J., Lee, G., Ritter, A., & Zhong, K. (2021). Lecanemab: A Phase 3 Randomized Controlled Trial for Early Alzheimer’s Disease. Alzheimer's & Dementia, 17(S9), e060444. https://doi.org/10.1002/alz.060444
More… ↓
⤷ Start Trial
|
